Healthcare solutions company Evolent Health (NYSE:EVH) will be reporting results tomorrow after market close. Here’s what to expect.
Evolent Health missed analysts’ revenue expectations by 1% last quarter, reporting revenues of $621.4 million, up 21.6% year on year. It was a slower quarter for the company, with full-year EBITDA guidance missing analysts’ expectations and a significant miss of analysts’ EPS estimates.
Is Evolent Health a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Evolent Health’s revenue to grow 17% year on year to $650.8 million, slowing from the 45.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.01 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Evolent Health has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Evolent Health’s peers in the healthcare technology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Premier’s revenues decreased 14.2% year on year, meeting analysts’ expectations, and Omnicell reported revenues up 18.6%, topping estimates by 2.2%. Premier traded down 14.3% following the results while Omnicell was also down 9.5%.
Read our full analysis of Premier’s results here and Omnicell’s results here.
Investors in the healthcare technology segment have had fairly steady hands going into earnings, with share prices down 2% on average over the last month. Evolent Health’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $18.31 (compared to the current share price of $10.10).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.